Lipella Pharmaceuticals Inc Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Lipella Pharmaceuticals Inc has an operating margin of -947.2%, meaning the company retains $-947 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -1055.5% the prior year.
Lipella Pharmaceuticals Inc's revenue surged 19.3% year-over-year to $536K, reflecting rapid business expansion. This strong growth earns a score of 84/100.
Lipella Pharmaceuticals Inc carries a low D/E ratio of 0.39, meaning only $0.39 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 97/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 3.47, Lipella Pharmaceuticals Inc holds $3.47 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Lipella Pharmaceuticals Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Lipella Pharmaceuticals Inc generates $0.79 in operating cash flow (-$4.0M OCF vs -$5.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Lipella Pharmaceuticals Inc (LIPO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Lipella Pharmaceuticals Inc generated $536K in revenue in fiscal year 2024. This represents an increase of 19.3% from the prior year.
Lipella Pharmaceuticals Inc's EBITDA was -$5.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 7.0% from the prior year.
Lipella Pharmaceuticals Inc reported -$5.0M in net income in fiscal year 2024. This represents a decrease of 8.6% from the prior year.
Lipella Pharmaceuticals Inc earned $-4.79 per diluted share (EPS) in fiscal year 2024. This represents an increase of 22.2% from the prior year.
Lipella Pharmaceuticals Inc held $2.2M in cash against $0 in long-term debt as of fiscal year 2024.
Lipella Pharmaceuticals Inc had 1M shares outstanding in fiscal year 2024. This represents an increase of 59.8% from the prior year.
Lipella Pharmaceuticals Inc's operating margin was -947.2% in fiscal year 2024, reflecting core business profitability. This is up 108.3 percentage points from the prior year.
Lipella Pharmaceuticals Inc's net profit margin was -935.2% in fiscal year 2024, showing the share of revenue converted to profit. This is up 92.1 percentage points from the prior year.
Lipella Pharmaceuticals Inc invested $3.6M in research and development in fiscal year 2024. This represents an increase of 18.9% from the prior year.
LIPO Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $87K-33.0% | $129K-25.5% | $174K+27.3% | $136K-6.5% | $146K+20.7% | $121K+16.1% | $104K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $721K-8.9% | $792K-20.3% | $993K-6.5% | $1.1M+60.6% | $662K-21.5% | $843K+85.5% | $454K-45.5% | $833K |
| SG&A Expenses | $553K-15.1% | $652K+40.5% | $464K-17.6% | $563K+31.7% | $427K-18.0% | $521K+31.5% | $396K-36.9% | $628K |
| Operating Income | -$1.3M+6.1% | -$1.4M-2.2% | -$1.3M+8.5% | -$1.5M-52.4% | -$952K+21.8% | -$1.2M-66.9% | -$730K+46.2% | -$1.4M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$1.3M+5.5% | -$1.3M-1.6% | -$1.3M+9.4% | -$1.4M-53.7% | -$938K+21.3% | -$1.2M-73.0% | -$689K+48.0% | -$1.3M |
| EPS (Diluted) | $-0.28+9.7% | $-0.31+51.6% | $-0.64+46.7% | $-1.20 | $-0.99+24.4% | $-1.31 | $-3.86 | $-1.84 |
LIPO Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.3M-36.8% | $3.7M-23.4% | $4.9M+81.6% | $2.7M+22.4% | $2.2M-30.4% | $3.1M-12.3% | $3.6M+25.9% | $2.8M |
| Current Assets | $2.1M-39.5% | $3.4M-28.7% | $4.8M+84.3% | $2.6M+25.8% | $2.1M-30.9% | $3.0M-12.2% | $3.4M+28.4% | $2.7M |
| Cash & Equivalents | $1.9M-33.3% | $2.8M-34.2% | $4.2M+93.4% | $2.2M+84.1% | $1.2M-43.6% | $2.1M-36.1% | $3.3M+36.7% | $2.4M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | $85K+139.8% | $35K-48.7% | $69K+113.5% | $32K-39.2% | $53K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $862K-11.9% | $979K+26.0% | $777K+3.0% | $754K+57.1% | $480K-16.6% | $576K+33.1% | $433K-30.1% | $619K |
| Current Liabilities | $642K-14.0% | $747K-3.9% | $777K+3.0% | $754K+57.1% | $480K-13.0% | $552K+43.2% | $385K-29.8% | $549K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $1.5M-45.7% | $2.7M-32.8% | $4.1M+112.5% | $1.9M+12.7% | $1.7M-33.5% | $2.6M-18.5% | $3.1M+41.5% | $2.2M |
| Retained Earnings | -$19.2M-7.0% | -$18.0M-8.0% | -$16.6M-8.5% | -$15.3M-23.2% | -$12.5M-8.1% | -$11.5M-11.5% | -$10.3M-7.1% | -$9.6M |
LIPO Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$926K+35.4% | -$1.4M-0.5% | -$1.4M-44.0% | -$990K-7.8% | -$919K+33.8% | -$1.4M-90.8% | -$728K-5.6% | -$689K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | $0 | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | -$728K | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | $0 | N/A |
| Financing Cash Flow | $0+100.0% | -$10K-100.3% | $3.5M+90.3% | $1.8M | $0-100.0% | $200K-87.6% | $1.6M | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
LIPO Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | -1564.2%-538.0pp | -1026.2%-190.5pp | -835.7%-137.7pp | -697.9%+136.8pp | -834.7%-230.9pp | -603.8%+700.1pp | -1303.9% |
| Net Margin | N/A | -1530.7%-520.9pp | -1009.8%-179.6pp | -830.1%-142.5pp | -687.6%+129.4pp | -817.0%-246.9pp | -570.1%+702.0pp | -1272.0% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -53.4%-17.7pp | -35.7%-8.8pp | -26.9%+27.0pp | -53.9%-11.0pp | -43.0%-5.0pp | -38.0%-18.7pp | -19.3%+27.3pp | -46.6% |
| Current Ratio | 3.24-1.4 | 4.60-1.6 | 6.21+2.7 | 3.47-0.9 | 4.33-1.1 | 5.46-3.4 | 8.90+4.0 | 4.87 |
| Debt-to-Equity | 0.58+0.2 | 0.36+0.2 | 0.19-0.2 | 0.39+0.1 | 0.28+0.1 | 0.22+0.1 | 0.14-0.1 | 0.28 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | -602.2% | N/A |
Similar Companies
Frequently Asked Questions
What is Lipella Pharmaceuticals Inc's annual revenue?
Lipella Pharmaceuticals Inc (LIPO) reported $536K in total revenue for fiscal year 2024. This represents a 19.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Lipella Pharmaceuticals Inc's revenue growing?
Lipella Pharmaceuticals Inc (LIPO) revenue grew by 19.3% year-over-year, from $450K to $536K in fiscal year 2024.
Is Lipella Pharmaceuticals Inc profitable?
No, Lipella Pharmaceuticals Inc (LIPO) reported a net income of -$5.0M in fiscal year 2024, with a net profit margin of -935.2%.
What is Lipella Pharmaceuticals Inc's earnings per share (EPS)?
Lipella Pharmaceuticals Inc (LIPO) reported diluted earnings per share of $-4.79 for fiscal year 2024. This represents a 22.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Lipella Pharmaceuticals Inc's EBITDA?
Lipella Pharmaceuticals Inc (LIPO) had EBITDA of -$5.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Lipella Pharmaceuticals Inc's operating margin?
Lipella Pharmaceuticals Inc (LIPO) had an operating margin of -947.2% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Lipella Pharmaceuticals Inc's net profit margin?
Lipella Pharmaceuticals Inc (LIPO) had a net profit margin of -935.2% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Lipella Pharmaceuticals Inc's operating cash flow?
Lipella Pharmaceuticals Inc (LIPO) generated -$4.0M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Lipella Pharmaceuticals Inc's total assets?
Lipella Pharmaceuticals Inc (LIPO) had $2.7M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Lipella Pharmaceuticals Inc spend on research and development?
Lipella Pharmaceuticals Inc (LIPO) invested $3.6M in research and development during fiscal year 2024.
How many shares does Lipella Pharmaceuticals Inc have outstanding?
Lipella Pharmaceuticals Inc (LIPO) had 1M shares outstanding as of fiscal year 2024.
What is Lipella Pharmaceuticals Inc's current ratio?
Lipella Pharmaceuticals Inc (LIPO) had a current ratio of 3.47 as of fiscal year 2024, which is generally considered healthy.
What is Lipella Pharmaceuticals Inc's debt-to-equity ratio?
Lipella Pharmaceuticals Inc (LIPO) had a debt-to-equity ratio of 0.39 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Lipella Pharmaceuticals Inc's return on assets (ROA)?
Lipella Pharmaceuticals Inc (LIPO) had a return on assets of -187.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Lipella Pharmaceuticals Inc's cash runway?
Based on fiscal year 2024 data, Lipella Pharmaceuticals Inc (LIPO) had $2.2M in cash against an annual operating cash burn of $4.0M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Lipella Pharmaceuticals Inc's Piotroski F-Score?
Lipella Pharmaceuticals Inc (LIPO) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Lipella Pharmaceuticals Inc's earnings high quality?
Lipella Pharmaceuticals Inc (LIPO) has an earnings quality ratio of 0.79x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Lipella Pharmaceuticals Inc?
Lipella Pharmaceuticals Inc (LIPO) scores 70 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.